Total and high-molecular-weight adiponectin levels and prediction of insulin resistance
Abstract
Introduction: Adiponectin is a peptide secreted by adipocytes; its reduction is associated with obesity-related disorders, including insulin resistance (IR). The study analysed levels of total adiponectin and its high-molecular-weight (HMW) oligomer in a group of metabolically healthy adults and in patients with type 2 diabetes mellitus (T2DM) to evaluate these levels as potential predictors of the presence of IR.
Materials and methods: The study comprised 269 metabolically healthy adults and 300 patients with T2DM. Anthropometric and biochemical indices were measured, including total and HMW adiponectin levels; the Homeostatic Model Assessment of IR (HOMA-IR) index was calculated, and logistic regression analysis was used to predict the presence of IR.
Results: In healthy individuals, both total and HMW adiponectin levels were significantly higher than in diabetic patients. Total and HMW adiponectin levels were moderately correlated with the HOMA-IR index. Logistic regression analysis showed that increased levels of both total adiponectin (odds ratio [OR] 0.598, 95% confidence interval [CI] 0.483–0.723) and the HMW form (OR 0.360, 95% CI 0.242–0.511) are protective factors for the development of IR. The cut-off levels were 4.22 mg/L for total adiponectin and 2.75 mg/L for HMW adiponectin. The results are valid for middle-aged European adults.
Conclusions: Adiponectin levels below the indicated cut-offs may predict a potential risk for the development of IR.
Keywords: total adiponectinhigh molecular weight adiponectininsulin resistanceodds ratiopredictionscut-off points
References
- Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol. 2014; 13: 103.
- Ghadge AA, Khaire AA, Kuvalekar AA. Adiponectin: A potential therapeutic target for metabolic syndrome. Cytokine Growth Factor Rev. 2018; 39: 151–158.
- Kuo SM, Halpern MM. Lack of association between body mass index and plasma adiponectin levels in healthy adults. Int J Obes (Lond). 2011; 35(12): 1487–1494.
- Mather KJ, Goldberg RB. Clinical use of adiponectin as a marker of metabolic dysregulation. Best Pract Res Clin Endocrinol Metab. 2014; 28(1): 107–117.
- Lim S, Quon MJ, Koh KK. Modulation of adiponectin as a potential therapeutic strategy. Atherosclerosis. 2014; 233(2): 721–728.
- Svačina Š, Souček M, Šmahelová A. Metabolický syndrom: nové postupy. Grada, Prague 2011.
- Inoue M, Maehata E, Yano M, et al. Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with type 2 diabetes. Metabolism. 2005; 54(3): 281–286.
- Yadav A, Kataria MA, Saini V, et al. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta. 2013; 417: 80–84.
- Katsiki N, Mantzoros C, Mikhailidis DP. Adiponectin, lipids and atherosclerosis. Curr Opin Lipidol. 2017; 28(4): 347–354.
- Evans JD. Straightforward Statistics for the Behavioral Sciences. Brooks-Cole Publishing, California 1996.
- Tang Qi, Li X, Song P, et al. Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in research and prospects for the future. Drug Discov Ther. 2015; 9(6): 380–385.
- Langenfeld MR, Forst T, Standl E, et al. IRIS II study. IRIS II Study: Sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance. Diabetes Technol Ther. 2004; 6(6): 836–843.
- Russo G, Baggio G, Rossi M, et al. Type 2 Diabetes and Cardiovascular Risk in Women. Int J Endocrinol. 2015; 2015: 1–2.
- Bilir BE, Güldiken S, Tunçbilek N, et al. The effects of fat distribution and some adipokines on insulin resistance. Endokrynol Pol. 2016; 67(3): 277–282.
- Savolainen O, Fagerberg B, Vendelbo Lind M, et al. Biomarkers for predicting type 2 diabetes development-Can metabolomics improve on existing biomarkers? PLoS One. 2017; 12(7): e0177738.
- Rojas E, Rodríguez-Molina D, Bolli P, et al. The role of adiponectin in endothelial dysfunction and hypertension. Curr Hypertens Rep. 2014; 16(8): 463.
- Ellulu MS, Patimah I, Khaza'ai H, et al. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017; 13(4): 851–863.
- Saisho Y, Hirose H, Roberts R, et al. C-reactive protein, high-molecular-weight adiponectin and development of metabolic syndrome in the Japanese general population: a longitudinal cohort study. PLoS One. 2013; 8(9): e73430.
- Li S, Shin HJ, Ding EL, et al. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009; 302(2): 179–188.
- Wannamethee SG, Sattar N, Rumley A, et al. Adipokines and risk of type 2 diabetes in older men. Diabetes Care. 2007; 30(5): 1200–1205.
- Snijder MB, Heine RJ, Seidell JC, et al. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the hoorn study. Diabetes Care. 2006; 29(11): 2498–2503.
- Webb DR, Khunti K, Chatterjee S, et al. Adipocytokine associations with insulin resistance in british South asians. J Diabetes Res. 2013; 2013: 561016.
- de Abreu VG, Martins CJ, de Oliveira PA, et al. High-molecular weight adiponectin/HOMA-IR ratio as a biomarker of metabolic syndrome in urban multiethnic Brazilian subjects. PLoS One. 2017; 12(7): e0180947.
- Sulistyoningrum DC, Gasevic D, Lear SA, et al. Total and high molecular weight adiponectin and ethnic-specific differences in adiposity and insulin resistance: a cross-sectional study. Cardiovasc Diabetol. 2013; 12: 170.
- de Luis DA, Pacheco D, Primo D, et al. The Association of SNP276G>T at Adiponectin Gene with Insulin Resistance and Circulating Adiponectin in Morbid Obese Patients After a Biliopancreatic Diversion Surgery. Obes Surg. 2017; 27(12): 3247–3252.
- Eglit T, Ringmets I, Lember M. Obesity, high-molecular-weight (HMW) adiponectin, and metabolic risk factors: prevalence and gender-specific associations in Estonia. PLoS One. 2013; 8(9): e73273.
- Nie JM, Li HF. Metformin in combination with rosiglitazone contribute to the increased serum adiponectin levels in people with type 2 diabetes mellitus. Exp Ther Med. 2017; 14(3): 2521–2526.
- Krysiak R, Żmuda W, Marek B, et al. Age may determine the effect of hypolipidemic agents on plasma adipokine levels in patients with elevated low-density lipoprotein cholesterol levels. Endokrynol Pol. 2016; 67(3): 271–276.
